Condition
NK-Cell Lymphoma
Total Trials
5
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
Early P 1 (1)
P 2 (1)
Trial Status
Recruiting3
Unknown2
Clinical Trials (5)
Showing 5 of 5 trials
NCT03719105Early Phase 1RecruitingPrimary
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
NCT05978141Recruiting
A Registry for People With T-cell Lymphoma
NCT05388838Not ApplicableRecruiting
Screening for Oculocerebral Lymphoma with the Phenotype of NK Cells in Patients with Uveitis
NCT03021057Phase 2Unknown
Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas
NCT03207789Unknown
T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients
Showing all 5 trials